US 12,474,321 B2
Nanopore protein conjugates for detection and analysis of analytes
Mark R. Ambroso, San Diego, CA (US); Kapil M.S. Bajaj, Newark, CA (US); and Timothy K. Craig, Campbell, CA (US)
Assigned to Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed by Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed on Aug. 11, 2020, as Appl. No. 16/990,602.
Application 16/990,602 is a continuation of application No. PCT/EP2019/053482, filed on Feb. 13, 2019.
Claims priority of provisional application 62/630,993, filed on Feb. 15, 2018.
Prior Publication US 2021/0033591 A1, Feb. 4, 2021
Int. Cl. G01N 33/487 (2006.01); C07K 14/31 (2006.01); G01N 33/543 (2006.01)
CPC G01N 33/48721 (2013.01) [C07K 14/31 (2013.01); G01N 33/54306 (2013.01); C07K 2319/40 (2013.01); C07K 2319/60 (2013.01)] 15 Claims
 
1. A nanopore protein conjugate comprising a nanopore protein monomer, an analyte attachment domain, and a capture tag, wherein (i) the capture tag comprises an amino acid sequence having at least 95% sequence identity to the amino acid sequence set forth as SEQ ID NO: 8, wherein (ii) the nanopore protein monomer of the nanopore protein conjugate comprises an amino acid sequence having at least 95% sequence identity to the sequence set forth as SEQ ID NO: 16 or SEQ ID NO: 6, and wherein (iii) the analyte attachment domain comprises an amino acid sequence that is located between the nanopore monomer and the capture tag.